PATENT CLAIM ANALYSIS

Application Number: 15772919
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["514", "394000"]

Abstract:
The present invention relates to a novel family of covalent kinases inhibitors. Compounds of this class have been found to have inhibitory activity against members of the Tec kinase family, particularly ITK, BTK, BMX, Tec and/or RLK. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvate of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof and its use in therapy.

Claim (Index 24):
A compound of  claim 1 , selected from the group consisting of:\n (a) a compound of Formula IIa: or pharmaceutically acceptable salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, wherein\n R is selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl; \n X\u2014Y is selected from the group consisting of: \u2014CH 2 \u2014NH\u2014Y, \u2014CH 2 \u2014NR 2 \u2014Y, \u2014CH 2 \u2014NR 3 \u2014Y, \u2014NR 2 C(O)\u2014Y, \u2014C(O)NR 2 \u2014Y, and \u2014CH 2 \u2014Y; \n wherein\n R 2  is hydrogen, lower alkyl or lower cycloalkyl; \n R 3  is \u2014C(O)R 4 , \u2014C(O)OR 4  or \u2014S(O) m R 4 , wherein m is an integer from 1 to 2; \n R 4  is lower alkyl or lower cycloalkyl; \n \n Y is selected from the group consisting of: hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, and substituted or unsubstituted heteroaralkyl,\n n 1  is an integer from 0 to 3; \n n 2  is an integer from 1 to 3; and \n R 1  is hydrogen, lower alkyl or lower cycloalkyl; \n \n (b) a compound of Formula IIb: or pharmaceutically acceptable salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, wherein R is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; X\u2014Y is: \u2014CH 2 \u2014NH\u2014Y, \u2014CH 2 \u2014NR 2 \u2014Y, \u2014CH 2 \u2014NR 3 \u2014Y, \u2014NR 2 C(O)\u2014Y, \u2014C(O)NR 2 \u2014Y, or \u2014CH 2 \u2014Y;\n wherein,\n R 2  is hydrogen, lower alkyl or lower cycloalkyl: \n R 3  is \u2014C(O)R 4 , \u2014C(O)OR 4  or-S(O) m R 4 , wherein m is an integer from 1 to 2: \n R 4  is lower alkyl or lower cycloalkyl: \n \n Y is selected from the group consisting of: hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, and substituted or unsubstituted heteroaralkyl, X 1  is hydrogen or halogen; and R 1  is hydrogen, lower alkyl or lower cycloalkyl; and (c) compound of Formula IIc: or pharmaceutically acceptable salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, wherein X\u2014Y is selected from the group consisting of: \u2014CH 2 \u2014NH\u2014Y, \u2014CH 2 \u2014NR 2 \u2014Y, \u2014CH 2 \u2014NR 3 \u2014Y, \u2014NR 2 C(O)\u2014Y, \u2014C(O)NR 2 \u2014Y, and \u2014CH 2 \u2014Y; wherein R 2  is hydrogen, lower alkyl or lower cycloalkyl; R 3  is \u2014C(O)R 4 , \u2014C(O)OR 4  or-S(O) m R 4 , wherein m is an integer from 1 to 2: R 4  is lower alkyl or lower cycloalkyl; Y is selected from the group consisting of: hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, and substituted or unsubstituted heteroaralkyl; and wherein ring B is a 3- to 8-membered substituted or unsubstituted heterocyclic ring.

Metadata:
- Claim Count in Document: 28.0
- Percentile: 93.0
- Lexical Diversity: 1.49123
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15262193', '14404497', '14412982', '15037923', '14009635']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8347980815210732
- 35 USC 102 Novelty (BERT): 0.5310190730412873
- Combined Prediction Score: 0.8044201806730946
- Mean Citation Score: 352.284728
- Max Citation Score: 364.62503
- Similarity Product: 243.2836333555448

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test